

<i>Product Licence Number</i>	<i>Company Name</i>	<i>Product Name</i>	<i>Active Ingredients</i>	<i>Indications</i>	<i>Date of Authorisation</i>
6679/0044 (continued)	Polyfarma Limited			Genito-urinary tract: Acute upper and lower urinary tract infections, bacterial prostatitis and male and female gonorrhoea. Gastro-intestinal tract: Typhoid and paratyphoid fevers, chronic carriage of Salmonella typhi and paratyphi, cholera as an adjunct to fluid and electrolyte replacement and shigellosis. Skin infections: Pyoderma, abscesses and wound infections. Other bacterial infections: Acute and chronic osteomyelitis, acute brucellosis, septicaemias and other infections caused by sensitive organisms.	
6679/0045	Polyfarma Limited	Septin Tablets	Co-Trimoxazole containing Sulphamethoxazole 400.0 mg Trimethoprim 80.0 mg	Prescription Only Medicine Same as in PL 6679/0044	12th August 1993
6679/0056	Polyfarma Limited	Zyloric 300 mg Tablets	Allopurinol 300.0 mg	Prescription Only Medicine Zyloric is used to reduce urate concentrations in body fluids and/or urine to prevent or reverse the deposition of urate/uric acid. Zyloric is indicated for the main clinical manifestations of urate/uric deposition. These are gouty arthritis, skin tophi and/or renal involvement through crystal deposition on stout formation. Such clinical manifestations occur in: idiopathic gout, uric acid lithiasis, acute uric acid nephropathy, neoplastic disease and myeloproliferative disease with high cell turnover rates, in which high urate levels occur either spontaneously or after cytotoxic therapy; certain enzyme disorders which lead to over production of urate and involve: hypoxanthine guanine phosphoribosyltransferase (including lesch-nyhan syndrome), glucose-6-phosphatase (including glycogen storage disease), phosphoribosylpyrophosphate synthetase, phosphoribosylpyrophosphate amidotransferase, adenine phosphoribosyltransferase, glutathione reductase, glutamate dehydrogenase. Zyloric is indicated for the management of 2,8-dihydroxyadenine (2,8-DHA) renal stones related to deficient activity of adenine phosphoribosyltransferase. Zyloric is indicated for the management of recurrent mixed calcium oxalate renal stones in the presence of hyperuricosuria, when fluid, dietary and similar measures have failed.	29th June 1993
6679/0057	Polyfarma Limited	Zyloric 300 mg Tablets	Allopurinol 300.0 mg	Prescription Only Medicine Same as in PL 6679/0056	26th June 1993
8142/0003	Norton (Waterford) Limited	Beclomethasone Dipropionate Inhaler 50.0 ug or Beclazone 50 Inhaler	Beclomethasone Dipropionate (as propellant 11 Solvate) HSE 50 ug	Prescription Only Medicine (i) Treatment of patients whose asthma is becoming worse, and the relief provided by bronchodilators is less effective. (ii) Treatment of patients with severe asthma who are dependent on systemic corticosteroids or adrenocorticotrophic hormone (ACTH) or its synthetic equivalent. (iii) Treatment of patients who are inadequately controlled by sodium cromoglycate in addition to bronchodilators. (iv) Particularly important for managing severe asthma in children because good control can be achieved without retardation of growth.	28th May 1993
8142/0004	Norton (Waterford) Limited	Beclomethasone Dipropionate Inhaler 100 ug or Beclazone 100 Inhaler	Beclomethasone Dipropionate (as propellant 11 Solvate) HSE 100.0 ug	Prescription Only Medicine Same as in PL 8142/0003	28th May 1993